Company: SMNR
Filing Date: 2025-04-22
Form Type: 8-K
Source: 0001213900-25-034254
Chunk: 0

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-22
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry into a Material Definitive Agreement.

As previously disclosed
in the Current Report on Form 8-K filed by Denali Capital Acquisition Corp. (“ Denali”) with the Securities and
Exchange Commission (the “SEC”) on September 5, 2024 (the “ Current Report”), on August 30, 2024,
Semnur Pharmaceuticals, Inc. (“ Semnur”), a Delaware corporation and wholly owned subsidiary of Scilex Holding Company
(“ Scilex”), entered into an agreement and plan of merger (the “ Merger Agreement”) with Denali, and
Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Denali (“ Merger Sub”), pursuant to which,
among other things, Merger Sub will merge with and into Semnur with Semnur surviving the merger as a wholly owned subsidiary of Denali
(the “Merger”). The Merger and the other transactions contemplated by the Merger Agreement are hereinafter referred
to as the “ Business Combination”. All capitalized terms used and not otherwise defined herein shall have
the meanings set forth in the Amendment (as defined below) and the Merger Agreement.